MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance

Basit Öğe Kaydı
dc.contributor.authorEcevit, Cigdem O.
dc.contributor.authorAktas, Safiye
dc.contributor.authorYildirim, Hulya Tosun
dc.contributor.authorDemirag, Bengu
dc.contributor.authorErbay, Ayse
dc.contributor.authorKaraca, Irfan
dc.contributor.authorCelik, Ahmet
dc.contributor.authorDemir, Ayse Banu
dc.contributor.authorErcetin, Ayse Pinar
dc.contributor.authorOlgun, Nur
dc.date.accessioned2019-10-27T09:59:19Z
dc.date.available2019-10-27T09:59:19Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractHepatoblastoma (HB) is the most common liver malignancy in children. The prognosis changes according to the histologic subtypes of HB. In the present study, we aimed to characterize the expression level of selected microRNAs (miRNAs) in HB as well as in histologic subtypes, and to consider the association with the prognosis. A total of 22 HB tumor samples, subtyped as fetal (n= 16) and embryonal (n= 6), and 10 nontumorous surrounding liver samples were evaluated in this study. Expressions of miR-17, miR-146a, miR-302d, and miR-19b were analyzed in 22 HB tumor samples and 10 nontumorous surrounding liver samples by quantitative real-time polymerase chain reaction. Lower miRNA-17 expression levels were obtained in tumor samples in comparison with nontumorous surrounding liver samples (P= 0.028). Lower miRNA-17 expression was significant for predicting prognosis in HB patients (area under receiver-operator characteristic curve= 0.875, P= 0.044). A higher-level of miR-19b was found in embryonal samples (P= 0.008). Overall and event-free survival was not found to correlate with miRNA expression levels (P> 0.05). This research finds miRNA-17 and miRNA-19b expression levels can provide important data on diagnosis and prognosis in HB showing different clinical behaviors.en_US
dc.identifier.doi10.1097/MPH.0000000000001234
dc.identifier.endpage12en_US
dc.identifier.issn1077-4114
dc.identifier.issn1536-3678
dc.identifier.issn1077-4114en_US
dc.identifier.issn1536-3678en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage7en_US
dc.identifier.urihttps://doi.org/10.1097/MPH.0000000000001234
dc.identifier.urihttps://hdl.handle.net/11454/29602
dc.identifier.volume41en_US
dc.identifier.wosWOS:000455186000005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Pediatric Hematology Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthepatoblastomaen_US
dc.subjectmicroRNAen_US
dc.subjectprognosisen_US
dc.titleMicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importanceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu